These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 3717079)

  • 21. A phase I study of chronic daily dosing of oral etoposide in combination with cisplatin for patients with advanced cancer.
    Fukuoka M; Masuda N; Negoro S; Takada M; Kudoh S; Kusunoki Y; Matsui K; Takifuji N; Tachikawa A; Kawahara M
    Cancer; 1991 Jul; 68(2):284-8. PubMed ID: 2070326
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
    Harper P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies.
    Britten CD; Rowinsky EK; Baker SD; Agarwala SS; Eckardt JR; Barrington R; Diab SG; Hammond LA; Johnson T; Villalona-Calero M; Fraass U; Statkevich P; Von Hoff DD; Eckhardt SG
    Clin Cancer Res; 1999 Jul; 5(7):1629-37. PubMed ID: 10430061
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase I pilot study of BCNU plus thymidine in patients with refractory cancer.
    Schultz MZ; Sandler AB; Durivage HJ; Cooper DL
    Cancer Invest; 1996; 14(3):218-24. PubMed ID: 8630682
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined carboplatin and cisplatin. Limited prospects for dose intensification.
    Waterhouse DM; Reynolds RK; Natale RB
    Cancer; 1993 Jun; 71(12):4060-6. PubMed ID: 8508371
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen.
    Atzpodien J; Lopez Hänninen E; Kirchner H; Franzke A; Körfer A; Volkenandt M; Duensing S; Schomburg A; Chaitchik S; Poliwoda H
    Eur J Cancer; 1995 Jun; 31A(6):876-81. PubMed ID: 7646914
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
    Kirchner HH; Atzpodien J; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tamoxifen modulation of cisplatin resistance in patients with metastatic melanoma. A biologically important observation.
    Mc Clay EF; Mc Clay ME; Albright KD; Jones JA; Christen RD; Alcaraz J; Howell SB
    Cancer; 1993 Sep; 72(6):1914-8. PubMed ID: 8364868
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase I-II trial of intraperitoneal cisplatin and alpha-interferon in patients with persistent epithelial ovarian cancer.
    Berek JS; Welander C; Schink JC; Grossberg H; Montz FJ; Zigelboim J
    Gynecol Oncol; 1991 Mar; 40(3):237-43. PubMed ID: 2013446
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
    Miller AA; Hargis JB; Lilenbaum RC; Fields SZ; Rosner GL; Schilsky RL
    J Clin Oncol; 1994 Dec; 12(12):2743-50. PubMed ID: 7527456
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
    Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cisplatin plus oral etoposide in the treatment of patients with advanced small cell lung cancer. Japan Clinical Oncology Group.
    Asamoto H; Kawahara M; Iwami F; Kuba M; Furuse K; Tamura T; Saijo N; Shimoyama M
    Jpn J Clin Oncol; 1998 Dec; 28(12):745-8. PubMed ID: 9879292
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase I/II study of cisplatin and vinorelbine chemotherapy in patients with advanced non-small cell lung cancer.
    Hotta K; Sekine I; Tamura T; Sawada M; Watanabe H; Kusaba H; Akiyama Y; Inoue A; Shimoyama T; Nokihara H; Ueda Y; Yamamoto N; Kunitoh H; Ohe Y; Kodama T; Saijo N
    Jpn J Clin Oncol; 2001 Dec; 31(12):596-600. PubMed ID: 11902490
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I trial of 5-fluorouracil, leucovorin, and cisplatin in combination.
    O'Dwyer PJ; Cornfeld MJ; Peter R; Comis RL
    Cancer Chemother Pharmacol; 1990; 27(2):131-4. PubMed ID: 2249328
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paclitaxel administered over 3 h followed by cisplatin in patients with advanced head and neck squamous cell carcinoma: a clinical phase I study.
    Schilling T; Heinrich B; Kau R; Herzog M; Quasthoff S; Diergarten K; Rastetter J; Hanauske AR
    Oncology; 1997; 54(2):89-95. PubMed ID: 9075777
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I evaluation of thio-TEPA in combination with cisplatin for advanced gynecologic malignancies.
    Sandles LG; Freedman RS; Raber MN; Kavanagh J; Edwards CL; Scott WR; Wharton JT
    Gynecol Oncol; 1990 Nov; 39(2):139-45. PubMed ID: 2121628
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dose ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomiting.
    Grunberg SM; Stevenson LL; Russell CA; McDermed JE
    J Clin Oncol; 1989 Aug; 7(8):1137-41. PubMed ID: 2526864
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I evaluation of preirradiation chemotherapy with carmustine and cisplatin and accelerated radiation therapy in patients with high-grade gliomas.
    Rajkumar SV; Buckner JC; Schomberg PJ; Pitot HC; Ingle JN; Cascino TL
    Neurosurgery; 1999 Jan; 44(1):67-73. PubMed ID: 9894965
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic study of trimetrexate in combination with cisplatin.
    Hudes GR; LaCreta F; Walczak J; Tinsley P; Litwin S; Comis RL; O'Dwyer PJ
    Cancer Res; 1991 Jun; 51(12):3080-7. PubMed ID: 1828188
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase I trial of cisplatin in hypertonic saline and escalating doses of 5-fluorouracil by continuous intravenous infusion in patients with advanced malignancies.
    Saltz L; Kelsen D
    Cancer; 1990 Oct; 66(8):1688-91. PubMed ID: 2208023
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.